Hepatocellular carcinoma (HCC) is one of the malignant tumors of the digestive system with the highest morbidity and mortality. The vast majority of patients with intermdiate and advanced HCC have low response rates and poor long-term survival to a series of treatments mainly based on transcatheter arterial chemoembolization (TACE). In recent years, molecular targeted therapy, immunotherapy and their combination with TACE have developed rapidly. This article reviews the research progress of TACE combined with systemic drug therapy in HCC and looks forward to the future direction of precise treatment of HCC.

Colorectal cancer (CRC)is one of the three major malignant tumors in the world with high morbidity and mortality. It is found that NPRL2 gene is closely related to the occurrence and development of CRC,and the expression of NPRL2 gene in CRC patients is significantly reduced. Oxaliplatin is the third generation of platinum anticancer drugs,and has been widely used in the chemotherapy of gastrointestinal tumors. Oxaliplatin can improve the survival rate of CRC patients,but some patients have drug resistance. NPRL2 gene can increase the sensitivity of oxaliplatin in the treatment of CRC,and is a potential target for treatment of CRC. This article reviewed the advances in study on NPRL2 gene and oxaliplatin in the treatment of CRC.